FDA clears targeted cholangiocarcinoma therapy
MDSpire News
September 24, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise:
3 Topic Commentaries
FDA clears targeted cholangiocarcinoma therapy
James J. Harding, MD
Gastrointestinal Medical Oncology
•Memorial Sloan Kettering Cancer Center
Marty Makary, MD, MPH
Public Health and Regulatory Policy
•U.S. Food and Drug Administration (FDA)
Tanios S. Bekaii-Saab, MD
Gastrointestinal Oncology
•Mayo Clinic Cancer Center
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.